News

Filter

Current filters:

evolocumabBiotechnology

1 to 9 of 13 results

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Amgen files for US approval of cholesterol drug evolocumab

28-08-2014

USA-based Amgen, the world's leading independent biotech firm, has filed a Biologics License Application…

AmgenBiotechnologyCardio-vascularChemistryevolocumabFamilial hypercholesterolemiaHealth Medical PharmaHigh cholesterolPCSK9RegulationUSA

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

1 to 9 of 13 results

Back to top